Ensifentrine, a new breakthrough in the treatment of chronic obstructive pulmonary disease in the world - detailed explanation by Ohtuvayre

Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease characterized by airflow limitation, chronic inflammation and decreased respiratory function. It is one of the leading causes of death in adults worldwide. In recent years, research on the treatment of COPD has continued to make breakthroughs. Among them, Ensifentrine-Ohtuvayre, a new inhaled drug, provides a new option for the maintenance treatment of COPD.

Exefentine has a unique mechanism of action. It inhibits phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) at the same time, which means that while improving bronchial smooth muscle relaxation, it can also reduce airway inflammation, thereby achieving a dual therapeutic effect. This dual-target mechanism allows exefantine to provide patients with a more precise and comprehensive lung function improvement strategy in addition to traditional bronchodilators and anti-inflammatory drugs.

Clinical studies have shown that exefantine can significantly improve quality of life by improving lung function, alleviating airway inflammation and improving patient symptoms. In patients with COPD, its effects include decreased airway resistance after inhalation, increased expiratory flow, and improvement in exercise tolerance and respiratory symptoms. In addition, the pharmaceutical dosage form of exefantine is an inhalation suspension solution, which can directly act on the airway mucosa to achieve local high-concentration drug effects while reducing the risk of systemic adverse reactions. This feature is particularly important in the maintenance treatment of COPD, because the disease is mostly long-term chronic management, and patients have higher requirements for drug tolerance and safety.

The research and development of Ohtuvayre also reflects the concept of precision medicine. Compared with traditional single PDE inhibitors, exefentine's dual-target design helps to simultaneously regulate airway inflammation and bronchial smooth muscle function, thereby providing more comprehensive disease control in early- and mid-stage COPD patients. In addition, the drug acts directly on the airways through the inhalation route, which can significantly reduce systemic exposure and reduce potential side effects on the cardiovascular system or other organs.

Reference: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ohtuvayre